KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares OutstandingShares Outstanding
Ratios

CRISPR Therapeutics AG (CRSP) Other Gross PP&E Adjustments (2016 - 2026)

CRISPR Therapeutics AG (CRSP) has disclosed Other Gross PP&E Adjustments for 11 consecutive years, with $56.4 million as the latest value for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments rose 33.12% to $56.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.4 million through Dec 2025, up 33.12% year-over-year, with the annual reading at $56.4 million for FY2025, 33.12% up from the prior year.
  • Other Gross PP&E Adjustments hit $56.4 million in Q4 2025 for CRISPR Therapeutics AG, down from $68.8 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $68.8 million in Q3 2025 to a low of -$79.5 million in Q2 2021.
  • Historically, Other Gross PP&E Adjustments has averaged $31.6 million across 5 years, with a median of $43.0 million in 2023.
  • Biggest YoY gain for Other Gross PP&E Adjustments was 513.01% in 2021; the steepest drop was 919.37% in 2021.
  • Year by year, Other Gross PP&E Adjustments stood at -$13.1 million in 2021, then skyrocketed by 271.58% to $22.5 million in 2022, then surged by 46.77% to $33.0 million in 2023, then rose by 28.18% to $42.4 million in 2024, then skyrocketed by 33.12% to $56.4 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for CRSP at $56.4 million in Q4 2025, $68.8 million in Q3 2025, and $65.3 million in Q2 2025.